Sorafenib in patients with locally advanced and metastatic chordomas: A phase II trial of the French Sarcoma Group (GSF/GETO)

Annals of Oncology

Volumn 26, Issue 10, 2015, Pages 2168-2173

  Bompas, E ^a   Le Cesne, A ^b   Tresch Bruneel, E ^c   Lebellec, L ^c   Laurence, V ^d   Collard, O ^e   Saada Bouzid, E ^f   Isambert, N ^g   Blay, J Y ^h   Amela, E Y ^c   Salas, S ⁱ   Chevreau, C ^j   Bertucci, F ^k   Italiano, A ^l   Clisant, S ^c   Penel, Nicolas ^c,m  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d INSTITUT CURIE   (France)

^e Institut de Cancerologie de la Loire   (France)

^f CENTRE ANTOINE LACASSAGNE   (France)

^g CENTRE GEORGES FRANÇOIS LECLERC   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ TIMONE HOSPITAL   (France)

^j INSTITUT CLAUDIUS REGAUD   (France)

^k INSTITUT PAOLI CALMETTES   (France)

^l INSTITUT BERGONIÉ   (France)

^m SIRIC OncoLille Consortium   (France)

more..

Author keywords

Chordoma; Phase II trial; Sorafenib

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; IMATINIB; SORAFENIB; THALIDOMIDE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ACUTE PANCREATITIS; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PATIENT; CHORDOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FRANCE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOKALEMIA; INTENTION TO TREAT ANALYSIS; KERATOACANTHOMA; LOSS OF APPETITE; LYMPHOCYTOPENIA; MALE; MEDICAL DOCUMENTATION; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NERVE PARALYSIS; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; SKIN MANIFESTATION; SKIN TOXICITY; SURVIVAL RATE; THYROTOXICOSIS; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR NECROSIS; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SARCOMA; SECONDARY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHORDOMA; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; SARCOMA; SURVIVAL RATE;

EID: 84943741986     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv300     Document Type: Article

References (18)

1. Walcott BP, Nahed BV, Mohyeldin A et al. Chordoma: current concepts, management and future directions. Lancet Oncol 2012;13: e69-e76.
2. Crockard HA, Steel T, Plowman N et al. A multidisciplinary team approach to skull base chordomas. J Neurosurg 2001; 95: 175-183.
3. Stacchiotti S, Casali PG, Lo Vullo S et al. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 2010; 17: 211-219.
4. Uhl M, Edler L, Jensen AD, Habl G et al. Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol. Radiat Oncol 2014;9: 100.
5. Lebellec L, Aubert S, Zairi F et al. Molecular targeted therapies in advanced or metastatic chordomas patients: facts and hypotheses. Crit Rev Oncol Hematol 2015; 95: 125-131.
6. Vieira de Castro C, Guimaraes G, Aguiar S et al. Tyrosine kinase receptor expression in chordomas: phosphorlyated AKT correlates inversely with outcome. Hum Pathol 2013; 44: 1747-1755.
7. Tamborini E, Miselli F, Negri T et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA and KIT receptors in chordomas. Clin Cancer Res 2006; 12: 6920-6928.
8. Li X, Ji Z, Ma Y et al. Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomas. Oncol Lett 2012; 3: 1268-1274.
9. Chen KW, Yang HL, Lu J et al. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. J Neurooncol 2011; 101:357-363.
10. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
11. Bayer Pharmaceuticals (8 21, 2003) Investigator's Brochure BAY 43-9006/Raf Kinase Inhibitor, Version No. 4.1.
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
13. Ray-Coquard I, Italiano A, Bompas E et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist 2012; 17: 260-266.
14. Chevreau C, Le Cesne A, Ray-Coquard I et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer 2013; 119: 2639-2644.
15. Valentin T, Fournier C, Penel N et al. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New Drugs 2013; 31: 1626-1627.
16. Stachiotti S, Longhi A, Ferraresi V et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol 2012; 30: 914-920.
17. Stacchiotti S, Tamborini E, Lo Vullo S et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol 2013; 24: 1931-1936.
18. Le Cesne A, Blay JY, Domont J et al. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-Dis): a randomised phase 2 trial. Lancet Oncol 2015;16: 312-319.